Recorded Presentation from the NCCN Pharmacy Updates: Ampullary Adenocarcinoma: Overview of Subtypes and Treatments
Ampullary adenocarcinoma is frequently grouped with biliary tract and pancreatic cancers due to its low prevalence. Because of its rarity, it is not a well-known or studied cancer in the community. Systemic therapies used to treat ampullary adenocarcinoma are complex and pharmacists play an important role in managing treatment, toxicity, and supportive care measures.
Category
  • Ampullary Adenocarcinoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Thyroid Carcinomas
Differentiated thyroid cancers have an excellent prognosis with appropriate treatment, and education in optimal management will help guide treatment decisions. For cases of thyroid cancer that require more aggressive treatment, knowledge of the most current treatment approaches can help clinicians give their patients a chance at the best possible outcome.
Category
  • Thyroid Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Identification and Management of Immuno-Oncology Targeted Therapy-Related Adverse Events in Renal Cell Carcinoma
The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving as new data continue to emerge for novel therapy options. As new immune checkpoint inhibitor (ICI)-based combinations continue to be developed, it is critical for clinicians to recognize and effectively manage immune-related adverse events associated with the ICIs in RCC to ensure maximum benefits from the treatment.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Recurrent/Metastatic Cervical Cancer and Neuroendocrine Carcinoma of the Cervix
The management of cervical cancer specific to histology, stage, and setting has changed tremendously and a review of new/latest data is important and helpful for the practitioners in treatment decision-making. Clinicians can benefit from continued education on comparing treatment options to best manage different histological types of cervical cancer.
Category
  • Cervical Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Advanced Ovarian Cancer
Due to the rapidly changing treatment landscape, clinicians in the community who treat advanced ovarian cancer may not be aware of new data. In order to optimize clinical outcomes, it is crucial for clinicians to be educated on this topic to ensure that they select the most appropriate treatment options for their patients with ovarian cancer.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Immunotherapy in Hepatocellular Carcinoma: Improving the Treatment Paradigm Within Community Practice
The goal of this program is to improve the knowledge and competence of learners to individualize the therapeutic management of patients with hepatocellular carcinoma (HCC).Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
Category
  • Hepatocellular Carcinoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Advances in Targeted Therapy for Biliary Tract Cancers
The landscape of targeted therapy continues to rapidly evolve, and pharmacists play an integral role on the interprofessional health care team. It is important for pharmacists to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, understanding the toxicities associated with these agents, and providing patient education.
Category
  • Hepatobiliary Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates in the Treatment of Adult Acute Lymphoblastic Leukemia
Side effects of novel therapies may be severe. Cytokine release syndrome, neurotoxicity, and sinusoidal obstruction syndrome (SOS/VOD) are just some of the serious adverse effects that may occur. With the expanding roles of monoclonal antibodies and CAR-T therapies in acute lymphoblastic leukemia (ALL), pharmacists should be aware of their proper place in therapy and side effect management for patient safety.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
NCCN Guidelines® Insights - Merkel Cell Carcinoma, Version 1.2024
These NCCN Guidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled “Clinical N0 Disease, Locally Advanced MCC.” This new algorithm page addresses locally advanced disease, and the panel clarifies the meaning behind the term “nonsurgical” by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.
Category
  • Skin Cancers
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Individualized Multidisciplinary CLL/SLL Care: Practical Application of Guidelines and Emerging Data
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Pages